Palisade Bio names Emil Chuang to board of directors

Palisade Bio, Inc. (NASDAQ: PALI) announced the appointment of Emil Chuang, MB BS FRACP, to its board of directors. The clinical-stage biopharmaceutical company focuses on developing therapeutics for autoimmune, inflammatory, and fibrotic diseases.

Chuang brings nearly 25 years of pharmaceutical and clinical experience across large pharma, biotech, therapeutics, medical nutrition, and diagnostics sectors. His expertise spans preclinical translational medicine through Phase 1-4 clinical development. His leadership contributed to two regulatory approvals: infliximab for pediatric Crohn's disease and lorcaserin for morbid obesity.

The pediatric gastroenterologist previously served as Assistant Professor at Duke University and the University of Pennsylvania before transitioning to the pharmaceutical industry. His work includes contributions to inflammatory bowel disease programs, including infliximab and vedolizumab.

"We are very pleased to welcome Emil to our Board of Directors. His extensive clinical development experience and deep understanding of IBD will provide valuable insight as we continue to execute our clinical programs," said JD Finley, Chief Executive Officer of Palisade Bio.

Chuang currently serves as Chief Medical Officer at Intrinsic Medicine, a privately held biotechnology company, and leads Chuang Global Consulting, his independent advisory firm. His previous roles include Head of GI Clinical Development for Nestlé Health Science, Head of GI Translational Research and Early Clinical at Takeda, and Head of GI Precision Medicine at Progenity.

He has authored more than 80 peer-reviewed publications, abstracts, and book chapters throughout his career. Chuang received his medical degree from the University of Sydney, Australia and completed pediatrics specialty training in Australia before moving to the United States for subspecialty training in pediatric gastroenterology and nutrition.

The information is based on a company press release statement.

You May Also Be Interested In

• Deere conference call: 2027 orders up mid-single digits from last year)
• Bessent on bonds: buyback could be more than 4 billion - CNBC
• Troops Inc. disputes short-seller report amid Hong Kong court proceedings